Lepu Biopharma (HKG:2157) said it will resubmit its new drug application for nasopharyngeal cancer drug MRG003 with necessary supplementary materials to China's National Medical Products Administration on March 4, according to a Tuesday filing with the Hong Kong bourse.
MRG003 is an antibody-drug conjugate that targets EGFR on tumor cells, delivering a potent chemotherapy drug released inside the cell to trigger cancer cell death.
Previously, the NDA application was accepted by the administrator in September 2024 and was later withdrawn by the pharmaceutical company.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。